Coronavirus: Johnson & Johnson defends efficacy rate of its one-shot COVID-19 vaccine

Mathai Mammen, head of research and development at Johnson & Johnson, defended the company’s one-shot coronavirus vaccine after newly-released data showed it was 66 per cent effective, behind Pfizer and Moderna. “It’s completely preventing the things that are most scary, which are going to hospital or worse,” he said.